Oxygen! ‘More or Less’ – The Benefits explained
R&D

Oxygen! ‘More or Less’ – The Benefits explained

Levitas Academy
14 January 2026
2 min read

Oxygen! 'More or Less' - The Benefits explained

Research Summary

Therapeutic Intermittent Hypoxia with a Hyperoxic “Chaser”

This summary explores the concept of Intermittent Hypoxic Training (IHT) with a hyperoxic “chaser,” a method involving cycles of low oxygen exposure followed by high oxygen, to induce beneficial physiological adaptation.

Background

Intermittent Hypoxic Training (IHT) is gaining traction across various medical fields, particularly in sports performance and wellness. IHT involves exposing individuals to short periods of low oxygen (hypoxia), followed by periods of normal or high oxygen (hyperoxia), to stimulate physiological adaptations.

Science and Physiology

  • IHT stimulates Hypoxia Inducible Factor-1 (HIF-1), a key cellular regulator in low oxygen, influencing more than 100 genes involved in adaptation.
  • Activation of HIF-1 promotes production of erythropoietin (EPO) and growth factors, boosts angiogenesis, and improves glucose metabolism.

Practical Application

Specialised equipment is used to safely modulate oxygen levels, providing hypoxic and hyperoxic phases. While popular in sports to boost performance, IHT is explored for therapeutic roles in cardiovascular disease, diabetes, obesity, and metabolic syndrome.

Supporting Evidence
  • Altitude Training Benefits: Evidence suggests IHT improves oxygen transport and VO₂-max, similar to altitude training adaptations.
  • Molecular Adaptations: Hypoxic exposure enhances vasodilation, mitochondrial efficiency, and oxygen delivery to muscles.
  • Clinical Applications: Early research indicates promising effects on metabolic health, cognitive function, and general wellness.
  • Safety and Efficacy: When carefully controlled, IHT is well tolerated with favorable risk-benefit profiles.
  • Combination Therapies: IHT may synergise with other treatments (e.g. cryotherapy or hyperbaric oxygen) to increase benefits.
  • Innovative Equipment: Advanced devices allow precise control of oxygen levels, improving safety and effectiveness.
  • Physiological Mechanisms: IHT activates protective systems such as antioxidant enzyme production and growth factor release.
  • Hormesis Effect: Moderate intermittent hypoxia is more beneficial than continuous or severe hypoxia, showing hormetic responses.
  • Population Observations: High-altitude populations show long-term adaptive benefits, supporting the concept.
  • Emerging Research: Ongoing studies continue to explore its use in both athletic and clinical populations.

Conclusion

Intermittent Hypoxic Training with a hyperoxic “chaser” is a promising strategy to harness natural adaptive processes. With the right protocol and equipment, it offers potential for both performance-enhancement and therapeutic application.

Further Reading / References

  • Research papers on IHT, HIF-1 activation, and intermittent hypoxia.
  • Clinical trials exploring IHT in metabolic and cardiovascular diseases.
  • Review articles on altitude training, hormesis, and adaptive physiology.
Explore Our Courses

Explore Our Courses

CPD-accredited courses in longevity, regenerative and functional medicine.

Browse Courses

More Articles

Related Posts

Vitamin D and Cognition
Wellbeing
18 August 20261 min read

Vitamin D and Cognition

Read Article
Vitamin D and the Safety of Higher Doses
R&D
18 August 20261 min read

Vitamin D and the Safety of Higher Doses

Read Article
Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing
R&D
14 January 20262 min read

Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing

Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing Summary: Methylene Blue and Red Light Therapy for Neuroprotection and Wellbeing Overview Methylene blue (MB) and red light therapy enhance mitochondrial function and provide neuroprotection. Together, they synergistically improve cognitive and overall health. Mechanism of Action Methylene Blue Electron Donor: MB donates electrons in the mitochondrial electron transport chain (ETC), enhancing oxygen delivery and ATP production. Inhibition of Nitric Oxide Synthase: Reduces nitric oxide production, stabilizing blood pressure and improving blood flow. Red Light Therapy Photon Donor: Near-infrared light penetrates tissues, stimulating cytochrome c oxidase (Complex IV), enhancing ATP synthesis and cellular respiration. Benefits Energy Levels: Improved mitochondrial function increases ATP production, enhancing physical stamina and reducing fatigue. Cognitive Function: Supports brain health, improving memory, focus, and mental clarity. Mood Regulation: MB acts as a mild MAOI, balancing neurotransmitters and alleviating depression and anxiety. Pain Management: Anti-inflammatory and analgesic effects support conditions like arthritis and migraines. Infection Control: MB’s antimicrobial properties help prevent infections and support immune resilience. Dosage and Administration Methylene Blue: 1–2 mg/kg body weight. Monitoring required above 7 mg/kg. IV dose ~50 mg weekly. Oral dose ~80 mg and titrated upward. Red Light Therapy: Applied transcranially in the 660–1064 nm red–NIR spectrum for optimal penetration. Research and Evidence Protection against Neurodegeneration Gonzalez-Lima and Auchter (2015) showed MB + NIR light enhances mitochondrial respiration and protects neurons. From Mitochondrial Function to Neuroprotection Tucker et al. (2018) demonstrated MB supports mitochondrial repair and may assist in Alzheimer’s and Parkinson’s treatment. Infrared Phototherapy Henderson and Morries (2015) found that NIR light improves cell survival, memory, and glucose metabolism. Neurological & Psychological Applications Rojas & Gonzalez-Lima (2013) showed transcranial lasers enhance blood flow and ATP production in neurons. References Gonzalez-Lima & Auchter, 2015 – Frontiers in Cellular Neuroscience Tucker et al., 2018 – Molecular Neurobiology Henderson & Morries, 2015 – Neuropsychiatric Disease and Treatment Rojas & Gonzalez-Lima, 2013 – Biochemical Pharmacology Wadsworth & Korthuis, 2012 – American Journal of Physiology Hamblin, 2017 – AIMS Biophysics Sahl et al., 2016 – Investigative Ophthalmology & Visual Science Bennett et al., 2016 – Cochrane Reviews Greco et al., 2001 – Journal of Bioenergetics Cassano et al., 2015 – Psychiatry Journal

Read Article

Keep Learning

Explore CPD-Accredited Courses

Browse the Levitas Academy course catalogue or get in touch with our team to find the right learning pathway.